Innoblative is working alongside Serumwerk Bernburg and MontesJura on EmboLog S, degradable starch microspheres for short term embolization in unresectable liver tumours.
Published
Signal category
Presence & Recognition
Quote
“Serumwerk Bernburg is hosting an EmboLog S user meeting during CIRSE congress week in Copenhagen”
— Nicola Capaldi|Innoblative team
Company
Innoblative
Our core values are to drive innovation, improve patient experience, and impact economics.
- Industry
- Medical Equipment Manufacturing
- Location
- Chicago, US
- Company size
- 13 employees
Innoblative is a private medical device company addressing clinical unmet needs for patients with breast cancer and other soft tissue diseases. We are developing advanced energy-based surgical solutions to help improve the way surgeons coagulate and ablate soft tissue to achieve better care for patients. Innoblative has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the company’s SIRA® RFA Electrosurgical Device. The SIRA® device is investigational for use in BCS and is not yet available for sale in the United States. The SIRA® device is cleared for intraoperative coagulation and ablation of soft tissue.
Founded 2013